Abstract Prostate cancer frequently acquires resistance to androgen receptor (AR)-targeted therapies through lineage plasticity, leading to neuroendocrine prostate cancer (NEPC), an aggressive and therapy-resistant subtype. BRN2 (POU3F2) is a key transcription factor that drives this transition and is normally repressed by AR signaling; however, the upstream mechanisms that activate BRN2 during therapy resistance remain poorly defined. We identify Polo-like kinase 1 (Plk1), a mitotic kinase upregulated in advanced disease, as a previously unrecognized upstream regulator of BRN2. Plk1 directly phosphorylates BRN2 at a conserved motif, enhancing its transcriptional activity and promoting downstream neuroendocrine reprogramming. Disruption of this phosphorylation markedly diminishes neuroendocrine marker expression and inhibits cellular plasticity. RNA-seq analysis further revealed suppression of EMT-associated transcriptional programs as a major downstream consequence of impaired BRN2 phosphorylation. In vivo, using a robust NEPC mouse model, inhibition of Plk1-dependent BRN2 activation reprograms tumor histology and molecular phenotype toward an AR-positive prostate adenocarcinoma (ARPC) state, indicating inhibition of lineage plasticity. These findings identify Plk1-mediated BRN2 phosphorylation as a critical driver of neuroendocrine transdifferentiation and highlight the Plk1-BRN2 axis as a promising therapeutic target to prevent NEPC progression in castration-resistant prostate cancer. Citation Format: Fatemeh Seilani, Meng Wu, Jia Peng, Mohammad Esfini Farahani, Xinyi Wang, Jinghui Liu, Yanquan Zhang, Ruixin Wang, Xiaoqi Liu. Plk1-BRN2 signaling axis drives lineage plasticity in castration-resistant prostate cancer abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5965.
Building similarity graph...
Analyzing shared references across papers
Loading...
Fatemeh Seilani
Meng Wu
Jia Peng
Cancer Research
University of Kentucky
Building similarity graph...
Analyzing shared references across papers
Loading...
Seilani et al. (Fri,) studied this question.
www.synapsesocial.com/papers/69d1fceba79560c99a0a29f7 — DOI: https://doi.org/10.1158/1538-7445.am2026-5965
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: